COMMUNIQUÉS West-GlobeNewswire

Biodesix to Participate in Upcoming Investor Conferences
21/05/2026
LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will participate in three upcoming [...]
Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia
21/05/2026
Cardiovascular and Respiratory medicines to be supplied in Malaysia and the Philippines Shin Hae-gon (right), Head of Overseas Sales at Hanmi Pharmaceutical, and Andreas Daugaard Jørgensen (left), Managing Director, [...]
Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference
21/05/2026
CHASKA, Minn., May 21, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that [...]
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
21/05/2026
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 year of follow-up post-dosing – – No relapses to-date [...]
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
21/05/2026
PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based [...]
Nanobiotix annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
21/05/2026
PARIS et CAMBRIDGE, Mass., 21 mai 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – « Nanobiotix » ou la « Société »), une société de biotechnologie au stade clinique et en phase avancée qui développe [...]
Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa
21/05/2026
Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa ( Pa ) Secondary objectives met with no immunogenicity observed, [...]
BioPorto announces Interim Result for the First Quarter of 2026
21/05/2026
May 21, 2026 Announcement no. 11 BioPorto announces Interim Result for the First Quarter of 2026 Copenhagen, Denmark, May 21, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), [...]
Concept Life Sciences Partners with OpenBench to Deliver Success-Based Drug Discovery Services for Early-Stage Biotech
21/05/2026
CHAPEL-EN-LE-FRITH, United Kingdom and SAN FRANCISCO, May 21, 2026 (GLOBE NEWSWIRE) -- Concept Life Sciences, a leading global contract research organization (CRO) with expertise in integrated drug discovery and [...]
Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting
21/05/2026
ORION CORPORATION PRESS RELEASE 21 MAY 2026 at 10:30 EEST Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM - 212 at the 2026 ASCO® Annual Meeting First clinical data from [...]
First quarter 2026 update: starting the year on track, with product innovation progress
21/05/2026
Louvain-la-Neuve, Belgium, 21 May 2026 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, shares its business update for the first quarter of 2026. Group Overview Solid commercial [...]
Déclaration Intermédiaire Premier Trimestre 2026: un début d’année sur la bonne voie, avec des avancées en matière d’innovation produits
21/05/2026
Louvain-la-Neuve, Belgique, le 21 mai 2026 - IBA (Ion Beam Applications SA), le leader mondial des technologies d’accélération de particules, publie aujourd'hui la revue de ses activités pour le premier trimestre 2026. [...]
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
21/05/2026
Pluvicto ® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancer Kisqali ® NATALEE oral presentation to report prognostic and [...]
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
21/05/2026
CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
NeuroZen Under Investigation - Critical Assessment Reveals Shocking Consumer Report Details Disclosed
21/05/2026
NeuroZen Scam or Legit, Consumer Complaints, Side Effects, Tinnitus Ear Health Ingredients, Does It Work, Pricing, and 60-Day Guarantee Explained Largo, FL, May 20, 2026 (GLOBE NEWSWIRE) -- These statements have not [...]
Sifts Microplastic Binding Supplement Claims Evaluated: The Chitosan Fiber Formula for Daily Microplastic Particle Exposure Support
21/05/2026
Chitosan's Electrostatic Fiber Mechanism, Ingredient-Level Research, and How the Formula Is Designed to Support Digestive Tract Particle Exposure Routines Daily Emmett, ID, May 20, 2026 (GLOBE NEWSWIRE) -- Disclaimer: [...]
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress
20/05/2026
State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026 $5.0 Million Private Placement Strengthens Cash Position to $4.2 Million as of March 31, 2026 Recent [...]
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis
20/05/2026
Virtual webinar to be held on Wednesday, May 27 at 11:00 AM ET LA JOLLA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe [...]
Cytokinetics to Hold Annual Meeting of Stockholders
20/05/2026
SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 27, 2026 at 10:00 AM Pacific [...]

Pages